Table of Content
- Introduction
- Definition of Dengue Vaccine Market
- Scope of the Report
- Methodology
- Executive Summary
- Market Overview
- Market Definition and Segmentation
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Porter's Five Forces Analysis
- PESTEL Analysis
- Dengue Vaccine Market, By Type
- Live Attenuated Vaccine
- Chimeric Live Attenuated Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Nucleic Acid Based Vaccine
- Dengue Vaccine Market, By Treatment
- Diuretic
- Chlorothiazide
- Chlorthalidone
- Hydrochlorothiazide
- Indapamide
- Anti-Allergic
- Cetirizine
- Desloratadine
- Fexofenadine
- Blood Thinners
- Apixaban
- Dabigatran
- Edoxaban
- Others
- Dengue Vaccine Market, By Route of Administration
- Oral
- Parenteral
- Others
- Dengue Vaccine Market, By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Dengue Vaccine Market, By End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Dengue Vaccine Market, By Geography
- North America
- United States
- Canada
- Europe
- United Kingdom
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of Middle East & Africa
- North America
- Competitive Landscape
- Company Profiles
- Mylan N.V. (U.S.)
- Company Overview
- Product Portfolio and Description
- Key Highlights
- Financial Overview
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- GSK plc (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- BIO-MED (India)
- Intercept Pharmaceuticals, Inc (U.K.)
- Emcure Pharmaceuticals Limited (India)
- Changchun BCHT Biotechnology Co. (China)
- Novo Medi Sciences (India)
- Mylan N.V. (U.S.)
- Conclusion and Future Outlook
- Appendix
- Research Methodology
- About the Pharmanucleus
- Disclaimer